AstraZeneca
US.AZN
162.70
-2.07
-1.26%
AstraZeneca
162.70
-2.07
-1.26%
Collector offline (last heartbeat: 19206s ago)
· 2026-09-04 20:02
Pre-market
162.79
-1.20%
After-hours
163.00
+0.18%
Overnight
165.15
+0.23%
Revenue annual, last 8 years
Latest year +8.63% YoY
Margins
- Gross margin
- 81.90%
- Operating margin
- 22.69%
- Net margin
- 17.41%
Key ratios & quality
- Enterprise value
- 274.34B
- PEG ratio
- 0.53
- Altman Z-Score
- 3.33
PEG uses trailing P/E against the 3-year net income growth rate (45.96%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.33, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 22.09B | 24.38B | 26.62B | 37.42B | 44.35B | 45.81B | 54.07B | 58.74B |
| Gross profit | 17.15B | 19.46B | 21.32B | 24.98B | 31.96B | 37.54B | 43.87B | 48.11B |
| Selling & admin expenses | 10.98B | 11.99B | 11.90B | 15.59B | 17.98B | 18.22B | 20.22B | 20.77B |
| Research & development | 5.93B | 6.06B | 5.99B | 9.74B | 9.76B | 10.94B | 13.58B | 14.23B |
| Operating profit | 516.00M | 1.74B | 3.92B | -139.00M | 4.51B | 8.72B | 10.25B | 13.33B |
| Pretax profit | 1.99B | 1.55B | 3.92B | -265.00M | 2.50B | 6.90B | 8.69B | 12.40B |
| Tax | -57.00M | 321.00M | 772.00M | -380.00M | -792.00M | 938.00M | 1.65B | 2.17B |
| Net profit | 2.05B | 1.23B | 3.14B | 115.00M | 3.29B | 5.96B | 7.04B | 10.23B |
| Basic EPS | 2 | 1 | 2 | 0 | 2 | 4 | 5 | 7 |
| Diluted EPS | 1.70 | 1.03 | 2.44 | 0.08 | 2.11 | 3.81 | 4.50 | 6.54 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 13.59B | 14.46B | 15.19B | 15.50B | 15.29B | 15.38B |
| Gross profit | 11.35B | 11.98B | 12.39B | 12.39B | 12.61B | 12.86B |
| Selling & admin expenses | 4.63B | 5.01B | 5.23B | 5.65B | 5.06B | 5.80B |
| Research & development | 3.16B | 3.55B | 3.66B | 3.86B | 3.49B | 4.05B |
| Operating profit | 3.67B | 3.51B | 3.58B | 2.98B | 4.25B | 3.16B |
| Pretax profit | 3.40B | 3.13B | 3.24B | 2.63B | 3.91B | 2.80B |
| Tax | 481.00M | 679.00M | 709.00M | 300.00M | 833.00M | 291.00M |
| Net profit | 2.92B | 2.45B | 2.54B | 2.33B | 3.08B | 2.51B |
| Basic EPS | 2 | 2 | 2 | 2 | 2 | 2 |
| Diluted EPS | 1.87 | 1.57 | 1.62 | 1.49 | 1.97 | 1.61 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 15.59B | 15.56B | 19.54B | 26.24B | 22.59B | 25.05B | 25.83B | 28.72B |
| Cash & ST investments | 5.59B | 6.22B | 7.99B | 6.40B | 6.24B | 5.86B | 5.53B | 5.72B |
| Inventory | 2.89B | 3.19B | 4.02B | 8.98B | 4.70B | 5.42B | 5.29B | 6.56B |
| Total assets | 60.65B | 61.38B | 66.73B | 105.36B | 96.48B | 101.12B | 104.04B | 114.07B |
| Total current liabilities | 16.29B | 18.12B | 20.31B | 22.59B | 26.29B | 30.54B | 27.87B | 30.62B |
| Short-term debt | 1.75B | 2.01B | 2.39B | 1.80B | 5.45B | 5.19B | 2.50B | 3.01B |
| Long-term debt | 17.36B | 15.73B | 17.51B | 28.13B | 22.97B | 22.37B | 26.51B | 24.72B |
| Total liabilities | 46,607,000,000.00 | 46,781,000,000.00 | 51,091,000,000.00 | 66,076,000,000.00 | 59,425,000,000.00 | 61,953,000,000.00 | 63,164,000,000.00 | 65,355,000,000.00 |
| Total equity | 14.04B | 14.60B | 15.64B | 39.29B | 37.06B | 39.17B | 40.87B | 48.72B |
| Retained earnings | 5.68B | 2.81B | 5.30B | 1.71B | -574.00M | 1.50B | 3.16B | 10.97B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 26.14B | 28.94B | 29.94B | 28.72B | 29.61B | 27.97B |
| Cash & ST investments | 5.40B | 7.11B | 8.18B | 5.74B | 7.68B | 4.97B |
| Inventory | 5.88B | 6.47B | 6.59B | 6.56B | 6.57B | 6.93B |
| Total assets | 106.25B | 112.42B | 114.46B | 114.07B | 114.02B | 115.83B |
| Total current liabilities | 29.13B | 33.54B | 34.05B | 30.62B | 32.57B | 31.55B |
| Short-term debt | 3.41B | 6.85B | 6.55B | 3.49B | 7.96B | 6.23B |
| Long-term debt | 26.69B | 24.71B | 24.70B | 24.72B | 24.45B | 23.68B |
| Total liabilities | 65,122,000,000.00 | 67,612,000,000.00 | 68,485,000,000.00 | 65,355,000,000.00 | 66,631,000,000.00 | 65,463,000,000.00 |
| Total equity | 41.13B | 44.81B | 45.97B | 48.72B | 47.38B | 50.37B |
| Retained earnings | 3.36B | 7.02B | 8.21B | 10.97B | 9.67B | 12.59B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2.62B | 2.97B | 4.80B | 5.96B | 9.81B | 10.35B | 11.86B | 14.58B |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- | -- | -- |
| Free cash flow | 1.25B | 509.00M | 2.19B | 3.76B | 7.24B | 6.57B | 7.28B | 8.67B |
| Dividends paid | -3.48B | -3.59B | -3.57B | -3.86B | -4.36B | -4.48B | -4.63B | -4.97B |
| Stock buybacks / issuance | 34.00M | 3.53B | 30.00M | 29.00M | 29.00M | 33.00M | -43.00M | -481.00M |
| Ending cash balance | 4.67B | 5.22B | 7.55B | 6.04B | 5.98B | 5.64B | 5.43B | 5.70B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 3.71B | 3.39B | 5.13B | 2.34B | 3.36B | 2.87B |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | 2.74B | 1.46B | 3.41B | 1.06B | 1.82B | -240.00M |
| Dividends paid | -3.35B | -10.00M | -1.61B | -3.00M | -3.29B | -1.00M |
| Stock buybacks / issuance | -478.00M | 1.00M | -14.00M | 10.00M | -602.00M | -40.00M |
| Ending cash balance | 5.21B | 7.03B | 8.08B | 5.70B | 7.51B | 4.88B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE % | 15.71 | 10.43 | 22.23 | 0.41 | 8.62 | -- | -- | 21.01 |
| ROA % | 3.48 | 2.19 | 4.99 | 0.13 | 3.26 | -- | -- | 8.96 |
| ROIC % | 9.79 | 7.35 | 12.31 | 2.09 | 6.31 | -- | -- | 14.47 |
| 5-year avg ROE % | 15.48 | 16.42 | 17.90 | 13.78 | 11.48 | -- | -- | -- |
| EBIT margin % | 15.21 | 12.10 | 19.49 | 2.70 | 8.64 | 18.53 | 19.18 | 23.86 |
| FCF / sales % | 5.65 | 2.09 | 8.24 | 10.06 | 16.32 | 14.34 | 13.45 | 14.76 |
| Current ratio | 0.96 | 0.86 | 0.96 | 1.16 | 0.86 | 0.82 | 0.93 | 0.94 |
| Quick ratio | 0.63 | 0.61 | 0.65 | 0.64 | 0.59 | 0.54 | 0.60 | 0.62 |
| Debt / assets | 153.30 | 138.85 | 130.46 | 78.15 | 78.69 | 72.57 | 73.83 | 59.89 |
| LT debt / equity | 139.23 | 123.54 | 115.18 | 73.57 | 63.96 | 59.33 | 67.72 | 53.70 |
| Interest coverage | 2.46 | 2.10 | 4.08 | 0.79 | 2.88 | 5.34 | 6.17 | 8.68 |
| Revenue CAGR (3Y) % | -3.66 | 1.96 | 5.82 | 19.20 | 22.07 | 19.84 | 13.06 | 9.82 |
| Net income CAGR (3Y) % | -8.63 | -27.47 | 2.12 | -62.68 | 35.05 | 23.05 | 297.51 | 45.96 |
| FCF CAGR (3Y) % | 32.51 | -34.74 | 3.85 | 44.51 | 142.26 | 44.14 | 24.58 | 6.21 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE % | 19.81 | 19.70 | 21.70 | 21.01 | 23.51 | 21.99 |
| ROA % | 7.45 | 7.65 | 8.57 | 8.96 | 9.43 | 9.15 |
| ROIC % | 12.27 | 12.48 | 14.01 | 14.47 | 14.90 | 14.39 |
| 5-year avg ROE % | -- | -- | -- | -- | -- | -- |
| EBIT margin % | 19.84 | 20.59 | 22.40 | 23.86 | 24.11 | 23.21 |
| FCF / sales % | 16.62 | 14.48 | 16.46 | 14.76 | 12.82 | 9.85 |
| Current ratio | 0.90 | 0.86 | 0.88 | 0.94 | 0.91 | 0.89 |
| Quick ratio | 0.64 | 0.63 | 0.66 | 0.68 | 0.67 | 0.61 |
| Debt / assets | 76.25 | 73.43 | 71.11 | 60.87 | 71.66 | 64.10 |
| LT debt / equity | 67.95 | 58.11 | 56.83 | 53.70 | 54.84 | 51.70 |
| Interest coverage | 6.74 | 7.22 | 8.24 | 8.68 | 8.79 | 8.60 |
| Revenue CAGR (3Y) % | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) % | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) % | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Pharmaceuticals100.00%
Region
US40.81%
China11.30%
Other8.56%
UK7.42%
Rest of Europe7.35%
Japan6.05%
Germany4.92%
Asia, Africa and Australasia4.63%
The Americas4.48%
Sweden4.47%
Quote time 2026-09-04 20:02:24
For reference only, not investment advice.